Voniza10 mg

Voniza is a potassium-competitive acid blocker (P-CAB) indicated for the following uses:

Established / Approved Indications

• Healing of erosive esophagitis (EE): Voniza is indicated for the healing of all grades of erosive esophagitis and relief of associated heartburn in adults.
• Maintenance of healed erosive esophagitis: Voniza is indicated to maintain healing of erosive esophagitis and relief of heartburn for up to 6 months.
• Relief of heartburn associated with non-erosive gastroesophageal reflux disease (GERD): short-term (4-week) use for symptomatic relief.
• Helicobacter pylori (H. pylori) eradication: Voniza is indicated in combination with antibiotics, as part of a triple therapy (with amoxicillin and clarithromycin) or dual therapy (with amoxicillin) regimen, to eradicate H. pylori infection. Voniza is not used alone for this purpose.

Other Uses

• Peptic ulcer disease: Voniza, as a potent acid suppressant, is used in the management of gastric and duodenal ulcers, including as part of H. pylori eradication regimens for ulcer-associated infection, in line with emerging clinical practice and guideline discussion, though this use may vary by local regulatory labeling.

Voniza belongs to a newer drug class (P-CABs) that is distinct from proton pump inhibitors (PPIs), though it is used for overlapping acid-related indications.

Each tablet of Vonoprazan contains Vonoprazan (as the fumarate salt) as the active pharmaceutical ingredient, along with pharmaceutically acceptable excipients. Vonoprazan is available in strengths such as 10 mg and 20 mg oral tablets. When used for H. pylori eradication, Vonoprazan is co-packaged or co-prescribed with amoxicillin, with or without clarithromycin, as part of a combination regimen.

Voniza is an orally administered potassium-competitive acid blocker (P-CAB), a class of gastric acid suppressants that is mechanistically and structurally distinct from proton pump inhibitors (PPIs). Voniza works by reversibly and competitively blocking potassium binding at the H+/K+-ATPase (the gastric "proton pump") on parietal cells, resulting in potent, rapid, and sustained inhibition of gastric acid secretion.

Voniza is used to heal erosive esophagitis, relieve heartburn associated with gastroesophageal reflux disease (GERD), and, in combination with antibiotics, to eradicate Helicobacter pylori infection. Compared with some PPIs, Voniza has a faster onset of acid suppression and does not require activation in an acidic environment, allowing more consistent acid control from the first dose.

Voniza belongs to the potassium-competitive acid blocker (P-CAB) class of gastric acid suppressants, a therapeutic category distinct from proton pump inhibitors (PPIs) and H2-receptor antagonists, though used for similar acid-related conditions.

Mechanism of Action

Vonoprazan is a potassium-competitive acid blocker (P-CAB). It reversibly and competitively inhibits the H+/K+-ATPase enzyme (the proton pump) on the luminal surface of gastric parietal cells by blocking potassium ion binding, thereby suppressing both basal and stimulated gastric acid secretion. Unlike proton pump inhibitors, which are prodrugs requiring acid activation and irreversible covalent binding, Vonoprazan accumulates in the acidic parietal cell canaliculus and binds to the proton pump in a pH-independent, non-covalent, and reversible manner.

Pharmacokinetics

• Absorption: Vonoprazan is rapidly absorbed after oral administration, with peak plasma concentrations reached within a few hours; it can be taken with or without food.
• Distribution: Vonoprazan is highly bound to plasma proteins.
• Metabolism: Vonoprazan is primarily metabolized by CYP3A4, with minor contributions from other CYP enzymes and sulfotransferases (SULT2A1).
• Elimination: Vonoprazan has a plasma half-life that supports once- or twice-daily dosing depending on indication, and its acid-suppressive effect begins on the first day of dosing without requiring gradual accumulation.

Voniza tablets are taken orally, swallowed whole with water, with or without food. For H. pylori eradication regimens, all component medicines (Voniza plus antibiotic(s)) must be taken together for the full prescribed course to ensure effective eradication and to reduce the risk of antibiotic resistance.

Voniza is contraindicated for concomitant use with rilpivirine-containing products (see Contraindications), because the profound and sustained acid suppression from Voniza significantly reduces rilpivirine absorption and plasma concentrations, risking loss of antiretroviral efficacy and HIV treatment failure.

Other Clinically Significant Interactions

• Drugs dependent on gastric pH for absorption (e.g., certain antiretroviral protease inhibitors such as atazanavir and nelfinavir, iron salts, ketoconazole, itraconazole, and certain other pH-dependent drugs): Voniza's marked acid suppression may reduce absorption and efficacy of these agents; avoid coadministration where possible or monitor clinical response closely.
• CYP3A4 inducers/inhibitors: Since Voniza is metabolized mainly by CYP3A4, strong CYP3A4 inducers (e.g., rifampin) may reduce Voniza plasma concentrations and efficacy, while strong CYP3A4 inhibitors may increase Voniza exposure; monitor for reduced effect or increased adverse effects accordingly.
• Digoxin: Acid-suppressing agents like Voniza may alter digoxin absorption; monitor digoxin levels when used together, particularly in elderly patients.
• Methotrexate (high-dose): Acid-suppressing drugs, as a class, have been reported to increase and prolong serum methotrexate concentrations in some patients receiving high-dose methotrexate; temporary withdrawal of Voniza may be considered in this setting under physician guidance.

Voniza is generally well tolerated. Reported adverse effects include:

Common

• Diarrhea
• Nausea and indigestion (dyspepsia)
• Abdominal pain and bloating
• Headache
• Elevated blood pressure
• Urinary tract infection

Less Common but Clinically Important

• Fundic gland polyps, particularly with long-term use beyond 1 year (see Precautions and Warnings)
• Low magnesium levels (hypomagnesemia) with prolonged use
• Vitamin B12 deficiency with long-term use
• Severe cutaneous adverse reactions (e.g., rash, in rare cases severe skin reactions)
• Acute interstitial nephritis (kidney inflammation) — rare

Patients should seek prompt medical attention for signs of severe allergic reaction, unexplained rash, severe or persistent diarrhea, muscle spasms, seizures, or unusual fatigue/weakness.

Pregnancy

Data on the use of Voniza in pregnant women are limited, and animal reproduction studies do not reliably predict human risk. Voniza should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Pregnant patients or those planning pregnancy should consult a physician before starting or continuing Voniza.

Lactation

It is not known whether Voniza is present in human milk or what effect it may have on a breastfed infant or on milk production. A decision should be made whether to discontinue breastfeeding or discontinue Voniza, taking into account the benefit of breastfeeding and the mother's clinical need for Voniza, and should be made in consultation with a physician.

• Masking of gastric malignancy: Symptomatic response to Voniza does not preclude the presence of gastric malignancy. Consider further evaluation in patients with an unsatisfactory response or early symptomatic relapse, particularly in patients at higher risk of gastric cancer.
• Fundic gland polyps: Long-term use (especially beyond one year) is associated with an increased risk of fundic gland polyps. Use the lowest effective dose for the shortest duration appropriate to the condition.
• Hypomagnesemia and mineral disturbances: Prolonged acid-suppressive therapy, including with Voniza, may lead to low magnesium, and secondarily low calcium and/or potassium, which can cause serious effects such as tetany, arrhythmias, and seizures. Consider periodic monitoring of magnesium in patients on prolonged therapy or those taking other drugs that can lower magnesium (e.g., diuretics).
• Vitamin B12 deficiency: Sustained acid suppression over long periods (typically ≥2–3 years) may reduce absorption of vitamin B12; monitor in patients on long-term therapy.
• Clostridioides difficile-associated diarrhea: Acid-suppressing medicines, as a class, may be associated with an increased risk of C. difficile-associated diarrhea, particularly in hospitalized patients; Voniza's specific long-term risk data are more limited than for established proton pump inhibitors, but the same precaution applies. Consider this diagnosis in patients with persistent diarrhea that does not improve.
• Severe cutaneous reactions: Discontinue Voniza immediately if signs of a severe skin reaction (e.g., blistering, widespread rash, mucosal involvement) occur, and seek medical attention.
• Hepatic impairment: Use with caution in patients with moderate-to-severe hepatic impairment; dose reduction is required for erosive esophagitis, and Voniza-based H. pylori regimens are not recommended (see Dosage and Administration).
• H. pylori combination therapy adherence: When Voniza is used with antibiotics for H. pylori eradication, patients must take the medicine exactly as prescribed by their physician, completing the full course without stopping, extending, skipping doses, or sharing the medicine with others, to ensure eradication and reduce the risk of antibiotic resistance.

Limited clinical experience is available with Voniza overdose. Based on its pharmacological profile, overdose would be expected to primarily cause exaggerated effects of profound gastric acid suppression. There is no specific antidote for Voniza overdose. In case of suspected overdose, seek immediate medical attention or contact a poison control center; treatment should be symptomatic and supportive, as directed by a physician. Do not attempt unsupervised home treatment for a suspected overdose.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

The safety and efficacy of Voniza in pediatric patients have not been established. Voniza is not recommended for use in children.

Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and younger adult patients, though greater sensitivity in some older individuals cannot be ruled out; no dose adjustment based on age alone is required.

Renal Impairment

No adjustment needed in mild-to-moderate impairment; dose reduction required in severe renal impairment for erosive esophagitis, and H. pylori regimens are not recommended (see Dosage and Administration).

Hepatic Impairment

No adjustment needed in mild impairment (Child-Pugh A); dose reduction required in moderate-to-severe impairment for erosive esophagitis, and H. pylori regimens are not recommended (see Dosage and Administration).

Duration of Voniza therapy depends on indication: 8 weeks for healing of erosive esophagitis, up to 6 months for maintenance therapy, 4 weeks for symptomatic relief of non-erosive GERD heartburn, and 14 days when used in combination with antibiotics for H. pylori eradication. Voniza should be used for the lowest effective dose and shortest duration appropriate to the clinical indication, and continued use beyond the recommended duration should be re-evaluated by a physician.

Potassium-competitive acid blocker (P-CAB); gastric acid suppressant. Vonoprazan is used, alone or in combination with antibiotics, for acid-related gastrointestinal conditions.

Vonoprazan reversibly and competitively blocks potassium binding at the gastric H+/K+-ATPase (proton pump) on parietal cells, producing potent, rapid, and sustained suppression of both basal and stimulated gastric acid secretion, without requiring acid activation as proton pump inhibitors do.

The safety and efficacy of Voniza have not been established in pediatric patients of any age group. Voniza is therefore not recommended for use in children and adolescents outside of a clinical trial setting. Use in this population should only be considered under direct specialist supervision if no suitable alternative exists, and only if a physician determines the potential benefit outweighs the unknown risks.